Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Vonoprazan Fumarate Tablets belong to the digestive system therapeutic class and are a novel potassium-competitive acid blocker (PCAB). Unlike traditional PPIs, they reversibly inhibit gastric H⁺/K⁺-ATPase and do not require acid-mediated activation. The product achieves rapid, stable and long-lasting acid suppression, providing consistent 24-hour control of gastric acid secretion regardless of meal timing.

This formulation is indicated for the treatment and maintenance therapy of reflux esophagitis, gastric ulcer, duodenal ulcer, and for Helicobacter pylori eradication in combination with suitable antibacterial agents.

Specifications: 10 mg, 20 mg

Packaging: Aluminium-plastic blister pack; 4 blisters × 7 tablets per box, 28 tablets/box.

Manufactured in full GMP compliance, the tablets conform to international quality standards, with stringent control over impurities, dissolution and stability. Our in-house API production ensures stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

As a favourable alternative to proton pump inhibitors, it boasts faster onset of action, fewer food-related administration restrictions and sustained therapeutic efficacy. Widely adopted in gastroenterology practice, it addresses the strong global demand for acid-related gastrointestinal disorder treatments.

We are able to supply qualified finished dosage forms, provide technology transfer, and negotiate other flexible cooperation arrangements. Feel free to contact us for full documentation, detailed specifications and cooperation terms.